http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2520661-C2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_86725a8deca7fe85feca96183c50f525 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_bc2b03342511abc88f60c63f2acd96d0 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-986 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-34 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-569 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K49-0013 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-52 |
| filingDate | 2009-08-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2014-06-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f2e6c7a5e188e302802b00a1bdec5c42 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d5ef536ab2c9401b24ed954120c5ac0c |
| publicationDate | 2014-06-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2520661-C2 |
| titleOfInvention | Using bacterial beta-lactamase for diagnosing in vitro and visualising, diagnosing and treating in vivo |
| abstract | FIELD: medicine, pharmaceutics. n SUBSTANCE: invention refers to microbiology, namely to using bacterial beta-lactamase for diagnosing in vitro and visualising, diagnosing and treating in vivo. A method for real-time detecting pathogenic bacteria in an individual consists in the fact that a fluorogenic substrate sample for bacterial beta-lactamase is administered into the individual or taken from the individual; visualising the individual or the sample for the presence of the fluorescent product of beta-lactamase activity on the substrate; generating signals at a wave length emitted by the fluorescent beta-lactamase product, and real-time detecting pathogenic bacteria in the individual. The fluorogenic substrate represents CNIR5, CNIR5-QSY22, CNIR7, CNIR7-TAT, CNIR9 or CNIR10. A method for monitoring the developing pathophysiological condition related to pathogenic bacteria in the individual. A method for screening the compounds possessing a therapeutic effect on pathogenic Mycobacterium in the individual. A method for visualising pathogenic bacteria with the fluorogenic substrate for bacterial beta-lactamase. n EFFECT: using the declared invention enables providing better visualisation of pathogenic bacteria and monitoring of efficacy of the therapeutic compounds. n 20 cl, 26 dwg, 1 tbl, 14 ex |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2776822-C2 |
| priorityDate | 2008-08-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 213.